

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Feige, et al.

Serial No.:

10/632,388

Group Art Unit No.:

1642

Filed:

July 31, 2003

Examiner: S. Huff

For:

MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.:

A-527C

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 form for consideration by the Examiner and provides a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Timothy Jugar

Attorney for Applicants Registration No.: 33,111

Phone: (805) 447-2688

Date: March 15, 2004

Please send all future correspondence to: U.S. Patent Operations/ [TJG] Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" label number:

EV352488825US

Date of Deposit:

Narch 15, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	_		Sheet	<u>1</u> C	Of 5
Modified Form PTO-1449	Atty.		Serial No.		
	Docket	A-527C		10/632.388	3
O 1 PLIST OF REFERENCES CITED BY APPLICANT	Applicant				
		Feige et al			_
(Use several sheets if necessary)	Filing	-	Group	•	
MAR 1 5 2004	Date	July 31, 2003		1642	

U.S. PATENT DOCUMENTS

TRADE	AART						
EXAMINER'S INITIAL'S		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A32	3,691,016	09/12/1972	Patel			
	A33	3,941,763	03/02/1976	Sarantakis			
	A34	3,969,287	07/13/1976	Jaworek et al.			
	A35	4,195,128	03/25/1980	Hildebrand et al.			
	A36	4,229,537	10/21/1980	Hodgins et al.			
	A37	4,247,642	01/27/1981	Hirohara et al.			
	A38	4,289,872	09/15/1981	Denkewalter et al.			
	A39	4,330,440	05/18/1982	Ayers et al.			
	A40	4,925,673	05/15/1990	Steiner et al.			
- · · · · · · · · · · · · · · · · · ·	A41	5,013,556	05/07/1991	Woodle et al.			
	A42	5,229,490	07/20/1993	Tam			
	A43	5,284,656	02/08/1994	Platz et al.			
	A44	5,792,451	08/11/1998	Sarubbi et al.			
	A45	5,376,367	12/27/94	Williams et al.			
					-		
							
				_,			
					- 		
							<u> </u>

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Drawline through citation is	f not in conformance and not considered. Include conv of this form with next

communication to applicant.

	Sheet	2	Of_	_ 5
Serial No.				
	10	7/632.	388	
				w · •

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket	A-527C	Serial No. 10/632.388	
Applicant			
	Feige et al		
Filing		Group	
Date	July 31, 2003	1642	

Modified Form PTO-1449

FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS CLASS YES NO						
EVAMINED'S AND	LUCHTENT NIMBED	DATE	COLLINA	CI ACC	CLASS	YES NO
B49	WO 93/21259	10/28/1993	PCT			
B50	WO 95/18858	07/13/1995	PCT			
B51	WO 95/21919	08/17/1995	PCT			
B52	WO 95/21920	08/17/1995	PCT			
B53	WO 95/26746	10/12/1995	PCT			
B54	WO 96/32478	10/17/1996	PCT			
B55	WO 96/40189	12/19/1996	PCT	*		
B56	WO 96/40750	12/19/1996	PCT	~~~		
B57	WO 98/25965	06/18/1998	PCT			
B58	WO 00/24770	05/04/2000	PCT			
B59	WO 00/24782	05/04/2000	PCT			
				 		
				-		
	<u> </u>				-	
<u> </u>		1		1		

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if communication to applicant.	not in conformance and not considered. Include copy of this form with next

		Sheet 3 Of S
Atty.		Serial No.
Docket	A-527C	10/632.388
Applicant		
	Feige et al	
Filing		Group
Date	July 31, 2003	1642

LIST OF REFERENCES CITED BY APPLICANT A-527C Applicant

(Use several sheets if necessary)

Modified Form PTO-1449

EXAMINER'S INITIALS		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
IPE	C113	Abuchowski et al. (1981), "Soluble Polymer - Enzyme Adducts," <i>Enzymes as Drugs</i> : Chapter 13, Hocenberg and Roberts, eds., Wiley-Interscience, New York, NY, pp. 367-383.
1 5 2004	14	Adjei et al. (1990), "Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers," <i>Pharmaceutical Research</i> 7:565-569.
OEMARK.	2 C115	Adjei et al. (1990), "Bioavailability of leuprolide following intratracheal administration to beagle dogs," International Journal of Pharmaceutics 61:135-144.
	C116	Alexander et al. (1996), "Deficiencies in Progenitor Cells of Multiple Hematopoietic Lineages and Defective Megakaryocytopoiesis in Mice Lacking the Thrombopoietin Receptor c-Mpl," <i>Blood</i> 87:2162-2170.
	C117	Bartley et al. (1994), "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," <i>Cell</i> 77:1117-1124.
	C118	Basser et al. (1996), "Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer," <i>The Lancet</i> 348:1279-1281.
	C119	Braquet et al. (1989), "Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig," <i>Journal of Cardiovascular Pharmacology</i> , 13 (Suppl.5):S143-S146.
	C120	Carosella et al. (1990), "Anti-Human Interleukin 2 Receptor Monoclonal Antibody Isotypic Switching: Chimeric Rat-Human Antibodies," <i>Human Immunology</i> 29:233-246.
	C121	Chang et al. (1995), "Cloning and Characterization of the Human Megakaryocyte Growth and Development Factor (MGDF) Gene," <i>The Journal of Biological Chemistry</i> 270:511-514.
	C122	Choi et al. (1995), "Platelets Generated In Vitro From Proplatelet-Displaying Human Megakaryocytes are Functional," <i>Blood</i> 85:402-413.
	C123	Clackson et al. (1995), "A Hot Spot of Binding Energy in a Hormone-Receptor Interface," <i>Science</i> 267:383-386.
	C124	Creighton, Thomas E., Proteins: Structures and Molecular Principles, W.H. Freeman and Company, New York, pp. 70-86 (1983)
	C125	Davis et al. (1985), "Preparation and Characterization of Antibodies with Specificity for the Amino- Terminal Tetrapeptide Sequence of the Platelet-Derived Connective Tissue," <i>Biochemistry International</i> 10:395-404.
	C126	Debili et al., (1995) "The Mpl Receptor is Expressed in the Megakaryocytic Lineage From Late Progenitors to Platelets," <i>Blood</i> 85:391-401.
	C127	Debs et al. (1988), "Lung-Specific Delivery of Cytokines Induces Sustained Pulmonary and Systemic Immunomodulation in Rats," <i>The Journal of Immunology</i> 140:3482-3488.
	C128	de Sauvage et al. (1994), "Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand," Nature 369:533-538.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line th communication to applicant.	rough citation if not in conformance and not considered. Include copy of this form with next

	And the same	Sheet 4 Of 5
Atty. Docket	A-527C	Serial No. 10/632.388
Applicant		
	Feige et al	
Filing Date	July 31 2003	Group 1642

1642

July 31, 2003

LIST OF REFERENCES CITED BY APPLICANT

Modified Form PTO-1449

(Use several sheets if necessary)

EXAMINER'S INITIALS		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
E	C129	Ellison et al. (1982), "The nucleotide sequence of a human immunoglobulin C _{γ1} gene," <i>Nucleic Acids Research</i> 10:4071-4079.
5 2004	130 2	Erickson et al., The Proteins, 3 rd ed., 2: Chapter 3, Solid-Phase Peptide Synthesis, Neurath et al., eds., Academic Press, New York, pp. 255-527 (1976)
ADEMARY	C131	Finn et al., The Proteins, 3 rd ed., 2: Chapter 2, Solid-Phase Peptide Synthesis, Neurath et al., eds., Academic Press, New York, pp. 105-253 (1976)
ALLEE .	C132	Fisher et al. (1996), "Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein," <i>The New England Journal of Medicine</i> 334:1697-1702.
	C133	Gurney et al. (1995), "Genomic Structure, Chromosomal Localization, and Conserved Alternative Splice Forms of Thrombopoietin," <i>Blood</i> 85:981-988.
	C134	Hokom et al. (1995), "Pegylated Megakaryocyte Growth and Development Factor Abrogates the Lethal Thrombocytopenia Associated With Carboplatin and Irradiation in Mice," <i>Blood</i> 86:4486-4492.
	C135	Hubbard et al. (1989), "Anti-Neutrophil-Elastase Defenses of the Lower Respiratory Tract in α 1-Antitrypsin Deficiency Directly Augmented with an Aerosol of α 1-Antitrypsin," <i>Annals of Internal Medicine</i> 111:206-212.
	C136	Kato et al. (1995), "Purification and Characterization of Thrombopoietin," <i>Journal of Biochemistry</i> 118:229 236.
	C137	Kaushansky et al. (1994), "Promotion of megakaryocyte progenitor expansion and differentiation by the c Mpl ligand thrombopoietin," <i>Nature</i> 369:568-571.
	C138	Kimura et al. (1999), "Peptide Mimetic of Thrombopoietin Stimulates Differentiation in Mouse Bone Marrow Cells," <i>Journal of Biochemistry, Molecular Biology & Biophysics</i> 2:281-286.
	C139	Kuter et al. (1994), "The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production," <i>Proceedings from the National Academy of Sciences USA</i> 91:11104-11108.
	C140	[DUPLICATE OF C137] Kaushansky et al. (1994), "Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo," <i>Nature</i> 369:565-568.
	C141	Love et al. (1989), "Recombinant Antibodies Possessing Novel Effector Functions," <i>Methods in Enzymalogy</i> 178:515-527.
	C142	Marshall, Keith, Modern Pharmaceutics, Chapter 10: Solid Oral Dosage Forms, G.S. Banker and C.T. Rhodes eds., School of Pharmacy, University of Bradford, Bradford, Yorkshire, England, pp. 359-427 (1979)
	C143	Merrifield, R.B. (1963), "Solid Phase Peptide Synthesis," <i>Journal of the American Chemical Society</i> 85:2149-2154.
	C144	Methia et al. (1993), "Oligodeoxynucleotides Antisense to the Proto-oncogene c-mpl Specifically Inhibit In Vitro Megakaryocytopoiesis," <i>Blood</i> 82:1395-1401.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if communication to applicant.	not in conformance and not considered. Include copy of this form with next

	Sheet	5	Of _	5
	Serial No.			
-527C	10/632.388			
eige et al				
	Group			

1642

LIST OF REFERENCES CITED BY APPLICANT

Modified Form PTO-1449

communication to applicant.

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **EXAMINER'S** INITIALS Palacios et al. (1985), "IL3-Dependent Mouse Clones That Express B-220 Surface Antigen, Contain Ig PE C145 Genes in Germ-Line Configuration, and Generates B Lymphocytes In Vivo," Cell 41:727-734. Rasko et al. (1997), "Mpl Ligand (MGDF) Alone and in Combination with Stem Cell Factor (SCF) BETT ADENCE MAR 1 5 2004 Promotes Proliferation and Survival of Human Megakaryocyte, Erythroid and Granulocyte/Macrophage **46** Progenitors," Stem Cells 15:33-42. Ravin et al., Remington Pharmaceutical Sciences, 18th ed., Chapter 75: Preformulation, pp. 1435-1712 C147 (1990)Roberts et al. (1997), "RNA-peptide fusions for the in vitro selection of peptides and proteins," C148 Proceedings from the National Academy of Sciences USA 94:12297-12302. Sheridan et al. (1997), "Biology of thrombopoiesis and the role of Mpl ligand in the production and functin C149 of platelets," Platelets 8:319-332. Smith et al. (1989), "Pulmonary Deposition and Clearance of Aerosolized Alpha-1 Proteinase Inhibitor C150 Administered to Dogs and to Sheep," Journal of Clinical Investigation 84:1145-1154. Stewart et al., Solid Phase Peptide Synthesis: Table of Contents and Indexes only, W.H. Freeman and C151 Company, San Francisco (1969) Syed et al. (1998), "Efficiency of signaling through cytokine receptors depends critically on receptor C152 orientation," Nature 395:511-516. Tai et al. (1990), "A Bifunctional Fusion Protein Containing Fc-Binding Fragment B of Staphylococcal C153 Protein A Amino Terminal to Antidigoxin Single-Chain Fv," Biochemistry 29:8024-8030. Ulich et al. (1995), "Megakaryocyte Growth and Development Factor Ameliorates Carboplatin-Induced C154 thrombocytopenia in Mice," Blood 86: 971-976. Vignon et al. (1992), "Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the metapoietic growth factor receptor superfamily," Proceedings C155 from the National Academy of Sciences USA 89:5640-5644. Wells et al. (1996), "Hematopoietic Receptor Complexes," Annual Review of Biochemistry 65:609-634. C156 Wrighton et al. (1996), "Increased Potency of an Erythropoietin Peptide Mimetic Through Covalent C157 Dimerization," Nature Biotech. 15:1261-1265. Wrighton et al. (1996), "Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin," C158 Science 273:458-463. Zeigler et al. (1994), "In Vitro Megakaryocytopoietic and Thrombopoietic Activity of c-mpl Ligand (TPO) on C159 Purified Murine Hematopoietic Stem Cells," Blood 84:4045-4052.

Atty. Docket

Applicant

July 31, 2003

Filing Date

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if	not in conformance and not considered. Include copy of this form with next